Tuesday, July 8, 2025
  • Home
  • National
  • International
  • Movies
  • Technology
  • Business
  • Fitness
  • Lifestyle
  • Punjab
  • Contact us
No Result
View All Result
No Result
View All Result
Home Business

Dr Reddy’s Labs share price outlook: Weak Revlimid sales to hurt as pharma grows; Check brokerage calls, target

by author
May 11, 2023
in Business
0
Dr Reddy’s Labs share price outlook: Weak Revlimid sales to hurt as pharma grows; Check brokerage calls, target
0
SHARES
28
VIEWS
Share on FacebookShare on Twitter


Dr Reddy’s Laboratories shares tanked 6.6% to Rs 4,545 today, pulling the Nifty Pharma down over 1% after the company posted a lower-than-expected EBITDA, net profit, and higher operating expenditure. Analysts attribute the weakness in net profit to the weak sales of gRevlimid medicine, a global blockbuster cancer drug. The company’s stock has fallen over 4% in the last one month while it has jumped over 7% year to date. In comparison, Nifty Pharma has jumped 3.4% in the last one month and is up nearly 1% YTD.

Overall the Indian pharmaceutical industry is expected to grow up to $130 billion in value by the end of 2030. According to estimates, in FY22 India exported pharmaceutical products worth $24.62 billion and it has been projected that exports will continue to grow in FY24. With the rise in exports, Dr Reddy is also expected to grow but analysts differ on how much the company will grow as gRevlimid demand is expected to fall in the next few years.

Dr Reddy’s growth outlook

Dr Reddy’s growth in India, Russia and other key markets was hit in FY23 by a very high base of FY22 but analysts expect growth to stabilize in FY24, with high single-digit to double-digit percentage growth. While the near-term growth prospects in various businesses remain decent, the potential earnings cliff in FY27 may weigh on the stock’s valuations.

Share Market Today, Share Market Live

Share Market LIVE: Nifty holds above 18300, Sensex up 50 pts; Bank Nifty above 43570, Adani Ent jumps 5%, Dr Reddy’s tank 6%

share market

Stocks To Watch: Dr Reddy’s, L&T, Procter & Gamble, Godrej Consumer, TII

Infosys share price outlook

Infosys share price outlook: Will June quarter be worse than March for IT? Check brokerage calls, target price

Nifty and Bank Nifty: Benchmark indices may remain volatile on F&O expiry.

Share Market outlook today: Nifty, Bank Nifty may remain volatile on F&O expiry; check support, resistance

Will gRevlimid sales continue to hit Dr Reddy’s balance sheet?

Analysts at Elara Capital believe that the gRevlimid opportunity materially will end in FY26 and FY27E could see a 40% drop in EPS. The Revlimid drug brought in nearly $10 billion in revenue for US-based Bristol Myers last year 2022. While Dr Reddy’s gRevlimid will remain the key growth/earnings driver for the company, there is a scope for the base business in the US to improve. The company has hinted at a significant number of product launches in the US in FY24 and improvement in the pricing scenario there.

Should you buy, sell or hold Dr Reddy’s Laboratories stock?

Elara Capital: Reduce – Target Price: Rs 4946 (8.8% upside)

“DRRD trades at 18.4x FY24E core earnings. With nearly half of the profits coming from gRevlimid which is set to go off in FY27, we see little upside to valuations/stock price. Our target price of Rs 4,946 is based on 17x FY25E core earnings of Rs 263 plus cash per share of Rs 483,” said analysts at Elara Capital. The brokerage said that any unforeseen large product opportunity in the US will be a key upside trigger, while lower-than-expected profits from gRevlimid would be a key downside risk.

Nuvama: Reduce – Target Price: Rs 4200 (7.6% downside)

“We are downgrading DRRD to ‘REDUCE’ despite gRevlimid strength as i) cracks show up in core US business and new launches can drive – at best – single-digit growth; ii) consistent IPM-beating growth in India not visible despite investments,” said analysts at Nuvama Institutional Equities.

Motilal Oswal: Neutral – Target Price: Rs 4500 (1% downside)

“We expect moderation in the earnings CAGR to 3.6% over FY23-25 due to a high base of FY23 and limited visibility of potential products to deliver growth over the next two years,” said analysts at Motilal Oswal. The brokerage believes the valuation already factors in the earnings upside, and maintains a Neutral rating on the stock.

JM Financial: Buy – Target Price: Rs 5980 (39.57% upside)

“The US base business ex-Revlimid is around $250mn, in our view, which should see some improvement from upcoming launches (25-30 in FY24),” said analysts at JM Financial. Analysts maintain BUY with a Mar’24 price target of Rs 5980 (including gRevlimid NPV of Rs 300).





Source link

Related posts

EXCLUSIVE – Crypto giant Binance controlled ‘independent’ US affiliate’s bank accounts

EXCLUSIVE – Crypto giant Binance controlled ‘independent’ US affiliate’s bank accounts

June 5, 2023
Why investing just to save tax may be bad for you

Why investing just to save tax may be bad for you

June 5, 2023
Previous Post

Karan Johar’s Dharma Productions and Guneet Monga Kapoor’s Sikhya Entertainment team up for content partnership : Bollywood News

Next Post

How tech enables safe mobility, Auto News, ET Auto

Related Posts

EXCLUSIVE – Crypto giant Binance controlled ‘independent’ US affiliate’s bank accounts
Business

EXCLUSIVE – Crypto giant Binance controlled ‘independent’ US affiliate’s bank accounts

June 5, 2023
Why investing just to save tax may be bad for you
Business

Why investing just to save tax may be bad for you

June 5, 2023
Share Market outlook today: Nifty, Bank Nifty may to gain on positive global cues; check support, resistance
Business

Share Market outlook today: Nifty, Bank Nifty may to gain on positive global cues; check support, resistance

June 5, 2023
Startup group of G20 calls for $1-trillion commitment
Business

Startup group of G20 calls for $1-trillion commitment

June 5, 2023
DHARAKSHA: Converting rice straw stubble to sustainable packaging material
Business

DHARAKSHA: Converting rice straw stubble to sustainable packaging material

June 4, 2023
Amrita Hospital, Kochi opens two new research centres; announces Rs 65 Crore for charitable care
Business

Amrita Hospital, Kochi opens two new research centres; announces Rs 65 Crore for charitable care

June 4, 2023
Next Post
How tech enables safe mobility, Auto News, ET Auto

How tech enables safe mobility, Auto News, ET Auto

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Inspired by policies of Delhi govt, BJP MCD councilor Gurjit Kaur Bath and Kulwant Singh Bath join AAP | India News

Inspired by policies of Delhi govt, BJP MCD councilor Gurjit Kaur Bath and Kulwant Singh Bath join AAP | India News

4 years ago
What is India’s Vehicle Scrappage Policy? All you need to know about the Voluntary Vehicle-Fleet Modernization Programme, ET Auto

What is India’s Vehicle Scrappage Policy? All you need to know about the Voluntary Vehicle-Fleet Modernization Programme, ET Auto

2 years ago
Fourth wave scare in Shanghai? China tries to limit economic blow of closed-down metropolis, disruptions to industry and trade | World News

Fourth wave scare in Shanghai? China tries to limit economic blow of closed-down metropolis, disruptions to industry and trade | World News

3 years ago
T20 World Cup 2021 Australia vs Pakistan: ‘Underdogs’ Oz can clinch title, says Brett Lee | Cricket News

T20 World Cup 2021 Australia vs Pakistan: ‘Underdogs’ Oz can clinch title, says Brett Lee | Cricket News

4 years ago

BROWSE BY CATEGORIES

  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fitness
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel

BROWSE BY TOPICS

Architecture culture Fitness indian architecture indian culture indian culture and heritage indian news lifestyle national news Technology technology news Travel travelling

About Us

Awaj Ludhiana Ki

Address

2667/3, Kishore Nagar, Tajpur & Jail Road, Ludhiana – 141008

Recent News

  • Gopal Khemka Murder Accused Killed In Police Encounter, JDU Leader Says CM Monitoring
  • How Russian Ministers Death Post-Dismissal Mirrors Critics Fate
  • Sarah Jane Dias joins the cast of Lakadbaggha 2 – The Monkey Business as Anshuman Jha welcomes her into the expanding animal-lover vigilante universe : Bollywood News
  • Over 25 Crore Workers To Strike Against Govt, Know Whats Open And Whats Closed?
  • RTI Reveals Spy Suspect Jyoti Malhotra Was Kerala Govts State Guest; Custody Extended Till July 21

Category

  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fitness
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel

Search

No Result
View All Result

Email

[email protected]

  • About
  • Advertise
  • Careers

Copyright © 2019 Awaj Ludhiana Ki or it's affiliates | Website by Awaj Ludhiana Ki Team

No Result
View All Result
  • Home
  • Contact us
  • Animals
  • Architecture
  • Automobiles
  • Business
  • Culture
  • Fashion
  • Fitness
  • Food
  • International
  • Lifestyle
  • Movies
  • National
  • Sports
  • Technology
  • Travel
  • Punjab

Copyright © 2019 Awaj Ludhiana Ki or it's affiliates | Website by Awaj Ludhiana Ki Team

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In